@prefix this: . @prefix sub: . @prefix np: . @prefix rdf: . @prefix xsd: . @prefix rdfs: . @prefix ns2: . @prefix ns1: . @prefix prov: . @prefix ns3: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { ns1:treat . } sub:provenance { sub:assertion prov:generatedAtTime "2021-12-16T20:03:01.560386"^^xsd:dateTime; prov:wasGeneratedBy "S&T TWOC project version 2" . sub:version prov:value "2"^^xsd:integer . rdf:OBJECT rdfs:label "hemophagocytic lymphohistiocytosis ( NK)/T-LAHLH ), a rare and fatal disease with no effective therapy" . rdf:OBJECT-POSITION rdfs:label "68"^^xsd:integer . rdf:PREDICATE rdfs:label "treating" . rdf:PREDICATE-POSITION rdfs:label "[95]" . rdf:SUBJECT rdfs:label "etoposide + dexamethasone-based chemotherapy regimens" . rdf:SUBJECT-POSITION rdfs:label "53"^^xsd:integer . rdfs:ABSTRACT-UID ns2:50 "3uitj0kw" . rdfs:SENTENCE rdfs:label "We evaluated whether etoposide + dexamethasone-based chemotherapy regimens might be useful for treating hemophagocytic lymphohistiocytosis (NK)/T-LAHLH), which is a rare and fatal disease with no effective therapy." . rdfs:TRIPLE-UID ns3:3uitj0kw-TRIPLE-ABSTRACT-4 "3uitj0kw-TRIPLE-ABSTRACT-4" . rdfs:label "disease" . rdfs:label "chemotherapy regimens" . } sub:pubInfo { sub:assertion prov:wasDerivedFrom . sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCSLeezU8JYlBsrgXOGXX4fxOq4oydsMzMK1CN0Rez2OEd2IYk18R4DetcZXwGhN3Pil7qcgNkiGvTirJXIo8zHl7jVehs19EdYtrttCKEaXRzWIr4LuCrfGedkvonEMWqR8e1GdQsLgEEyM50BD6Qw+srQt9ozcqf/9wG2MAMX9QIDAQAB"; npx:hasSignature "ZHQXMrCi14VTYPIHi4T4LSe6/KriQ5BomQ6ZhvRACxqKiBoxTHS6i2RBMX4QCb8+Hthuk9wW1xn3gIt+W4o2UyiFsZUYGSAhUUNAVRscfWRHPuHxRRrw8lWIPDAtZtGQPoZX+kmbJEOc+0g1YADJ0ChXMFA73P4cPRaFeyPgWRE="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2021-12-16T20:03:01.560386"^^xsd:dateTime; prov:wasAttributedTo . }